We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Technology for Making Nanoparticles

By Biotechdaily staff writers
Posted on 11 Jul 2005
A new technology breakthrough can create the world's tiniest manufactured particles for delivering drugs and biologic materials into the human body.

The technology provides control over shape, size, and composition of material when manufacturing nanoparticles. More...
This innovative new process has widespread applications, including drug formulation, drug delivery, medical imaging and disease detection, and nonmedical applications such as sensors, ink-jet printing, and microelectronics.

Called PRINT (particle replication in nonwetting templates), the technology enables the fabrication of custom-sized, monodispersed, and shape-specific particles of virtually any material and encapsulating nearly any active cargo. The latter includes delicate substances, biologic agents, and small molecules, which can be delivered through a full range of injectable, pulmonary, topical, and oral methods.

"This technique allows for development of a particle foundry, similar to continuous manufacturing techniques in the microelectronics industry, but for fabricating delicate particles for use in nanomedicines and other emerging technologies,” said Dr. W. Lowry Caudill, executive chairman of Liquidia Technologies (Research Triangle Park, NC, USA).

"Nanoparticle fabrication, until now, has focused on inorganic materials such as metals that involve harsh manufacturing methods and often are not useful for medical applications,” explained Joseph M. DeSimone, co-founder of Liquidia Technologies and professor of chemistry and chemical engineering at the University of North Carolina at Chapel Hill (USA). "This technology allows for the first time fabrication of particles for vaccines and therapies that are nontoxic for patients since the particles themselves are made from well-known bioabsorbable organic materials. Impressions are made with what we call liquid Teflon, and the resulting molds look something like ice cube trays with tiny cavities in them. After that, we mold the carrier and fragile functional materials into whatever particles we want.”






Related Links:
Liquidia Technologies

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.